Enveric Biosciences Inc (ENVB) Stock AnalysisENVBStock AnalysisEnveric Biosciences Inc

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Enveric Biosciences is not a good buy right now due to its significant ongoing losses and negative performance indicators. The current price is $1.37, with a year-to-date change of -62.67% and a one-year change of -89.53%. Additionally, the RSI is at 38.80, indicating that the stock is nearing oversold territory but has not yet shown signs of recovery. The main risk is the company's negative net income, which reached -$4,040,207 in Q4 2025, highlighting ongoing financial struggles.